Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.

Slides:

Advertisements

Similar presentations

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

Advertisements

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,

Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis by Katharine H.

A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma by Anamarija M. Perry, Teresa.

Volume 60, Issue 5, Pages (November 2011)

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Liver Cancer 2017;6: DOI: /

Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial.

Juvenile Myelomonocytic Leukemia

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia by Charles Koller,

Protease inhibitors potentiate chemotherapy-induced neutropenia

Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive.

A Novel Method of Amplification of FFPET-Derived RNA Enables Accurate Disease Classification with Microarrays P. Mickey Williams, Rui Li, Nathalie A.

by Fangxin Hong, Thomas M Habermann, Leo I

A novel hierarchical prognostic model of AML solely based on molecular mutations by Vera Grossmann, Susanne Schnittger, Alexander Kohlmann, Christiane.

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia by Jose Roman-Gomez, Antonio.

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

by Michael F. Leahy, and J. Harvey Turner

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Has MRD monitoring superseded other prognostic factors in adult ALL?

Global approach to the diagnosis of leukemia using gene expression profiling by Torsten Haferlach, Alexander Kohlmann, Susanne Schnittger, Martin Dugas,

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,

Stephen Ansell, MD, PhD Mayo Clinic

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL by Christian H. Geisler, Mars.

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232 by Michael J. Borowitz,

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue by David W. Scott,

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with.

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma by Paul M. Barr, Thomas P. Miller, Jonathan W. Friedberg,

Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi,

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Overall survival by SCT versus observation in first complete remission

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS by Takeshi Sugio, Kohta Miyawaki, Koji Kato, Kensuke Sasaki, Kyohei Yamada,

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen by Haris Ali, Ibrahim Aldoss, Dongyun.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL by Monika Pilichowska, Stefania Pittaluga,

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,

Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma.

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma per health-insurance (NHIF) status at diagnosis (P=0.003). Kaplan-Meier.

Impact of age on clinical risk scores in follicular lymphoma

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib by Chung H. Kok, David T.

Follicular Lymphoma International Prognostic Index

Patient stratification using survival risk prediction and BCLC staging

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Cold agglutinin disease

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Presentation transcript:

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette M. Staiger, Monika Szczepanowski, Heike Horn, Martin H. Dreyling, Andreas Rosenwald, German Ott, Wolfram Klapper, Andrew D. Zelenetz, Paul M. Barr, Jonathan W. Friedberg, Stephen Ansell, Laurie H. Sehn, Joseph M. Connors, Randy D. Gascoyne, Wolfgang Hiddemann, Michael Unterhalt, David M. Weinstock, and Oliver Weigert Blood Volume 128(8):1112-1120 August 25, 2016 ©2016 by American Society of Hematology

Progression of disease within 24 months (POD24) is an accurate predictor of poor overall survival (OS). Progression of disease within 24 months (POD24) is an accurate predictor of poor overall survival (OS). (A) Distribution of patients from the GLSG and BCCA cohorts according to the POD24 classifier. (B) Kaplan Meier curves for OS from risk-defining events for patients with or without POD24 of diagnosis (dashed lines) or 24 months of treatment initiation (solid lines) from the GLSG (left) and BCCA cohorts (right). Displayed statistics refer to POD24 status calculated from time of treatment initiation (ie, modified definition). Vindi Jurinovic et al. Blood 2016;128:1112-1120 ©2016 by American Society of Hematology

Accuracy of 3 pretreatment risk models to predict POD24 status. Accuracy of 3 pretreatment risk models to predict POD24 status. (A) Follicular Lymphoma International Prognostic Index (FLIPI), (B) m7-FLIPI, and (C) POD24 Prognostic Index (POD24-PI). Vindi Jurinovic et al. Blood 2016;128:1112-1120 ©2016 by American Society of Hematology

Risk stratification for failure-free survival (FFS) in patients without POD24 according to 3 pretreatment risk models. Risk stratification for failure-free survival (FFS) in patients without POD24 according to 3 pretreatment risk models. Kaplan-Meier curves for FFS beyond 2 years after treatment initiation for patients without POD24 according to (A) the FLIPI, (B) the m7-FLIPI, and (C) the POD24-PI. Numbers in parentheses indicate patients with event/number of patients per subgroup. Pie charts illustrate distribution of risk status of the respective risk classifier and POD24 status. Vindi Jurinovic et al. Blood 2016;128:1112-1120 ©2016 by American Society of Hematology

The POD24 Prognostic Index (POD24-PI). The POD24 Prognostic Index (POD24-PI). (A) The POD24-PI is calculated as the sum of individual clinical and gene mutation predictor values weighted by their individual coefficients. (B) Kaplan-Meier curves for failure-free survival (FFS), and (C) overall survival (OS) for patients from the GLSG and BCCA cohorts according to POD24-PI status. Numbers in parentheses indicate patients with event/number of patients per subgroup. Vindi Jurinovic et al. Blood 2016;128:1112-1120 ©2016 by American Society of Hematology

Identification of high-risk patients by 3 pretreatment risk models and POD24 status. Identification of high-risk patients by 3 pretreatment risk models and POD24 status. Venn diagrams visualize the overlap of high-risk patients as identified by the FLIPI, m7-FLIPI, POD24-PI, and POD24. Vindi Jurinovic et al. Blood 2016;128:1112-1120 ©2016 by American Society of Hematology